Roberto L. Patron

Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin

Michael W. Climo, Roberto L. Patron, Gordon L. Archer · Antimicrobial Agents and Chemotherapy · 1999 · 190 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Lysostaphin Treatment of Experimental Methicillin-Resistant <i>Staphylococcus aureus</i> Aortic Valve Endocarditis

Michael W. Climo, Roberto L. Patron, Beth P. Goldstein et al. · Antimicrobial Agents and Chemotherapy · 1998 · 136 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a <i>Staphylococcus aureus</i> Isolate with Reduced Susceptibility to Vancomycin

Roberto L. Patron, Michael W. Climo, Beth P. Goldstein et al. · Antimicrobial Agents and Chemotherapy · 1999 · 87 citations · Full text

Medicine, Infectious Diseases, Pharmacology +11

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients

Roy F. Chemaly, Sanjeet Dadwal, Anne Bergeron et al. · Clinical Infectious Diseases · 2019 · 75 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Zelalem Temesgen, Charles D. Burger, Jason Baker et al. · The Lancet Respiratory Medicine · 2021 · 74 citations · Full text

Pharmacy, Infectious Diseases, Internal Medicine +13